Guillain-Barré syndrome
Dr. Angelo Smith M.D
WHPL
Guillain-Barre’

It has an annual incidence of 0.6 to 2.4 cases per
100,000 population and occurs at all ages and in
both sexes
With the marked decline in the incidence of
polio, Guillain-Barré syndrome is now the most
common cause of acute flaccid paralysis in
healthy people
is an acute inflammatory demyelinating
polyneuropathy characterized by progressive muscle
weakness and areflexia
Guillain-Barre’ Syndrome
 Post-infectious polyneuropathy; ascending
polyneuropathic paralysis
 An acute, rapidly progressing and potentially fatal
form of polyneuritis
Guillain-Barre’ Syndrome
 Affects the peripheral nervous system

PATHOGENESIS
Peripheral nerve demyelination in
Guillain-Barré syndrome is believed to be
immunologically mediated
Humoral factors and cell-mediated
immune phenomena have been
implicated in the damage of myelin
and/or the myelin-producing Schwann
cells
Guillain-Barre’
T-cell sensitization occurs which causes
loss of myelin which disrupts nerve
impulses
Loss of myelin, edema and
inflammation of the affected nerves,
causes a loss of neurotransmission to
the periphery.
85% of patients recover with supportive
care.
Guillain-Barré syndrome has been reported to
follow
 vaccinations
 epidural anesthesia
 thrombolytic agents
It has been associated with some systemic
processes, such as
 Hodgkin's disease
 SLE
 Sarcoidosis, and
 infection with Campylobacter, Lyme disease, EBV,
CMV, HSV, mycoplasma, and recently acquired HIV
infection
Campylobacter infection
is the most commonly identified precipitant of
Guillain-Barré syndrome
A case-control study involving 103 patients
with the disease found that 26% of affected
individuals had evidence of recent C. jejuni
infection compared with 2% of household and
1% of age-matched controls
Seventy percent of those infected with C. jejuni
reported a diarrheal illness within 12 weeks
before the onset of the neurologic illness
Clinical Manifestations
 Usually develop 1 to 3 weeks after URI or GI
infection
 Weakness of lower extremities
(symmetrically)
 Parathesia (numbness and tingling), followed
by paralysis
 Hypotonia and areflexia (absence of reflexes)
 Pain in the form of muscles cramps or
hyperesthesias (worse at night).
Early in the course, patients frequently
complain of aching or sciatica-like lower back
or leg pain
At some point during their illness, up to 25
percent of patients require mechanical
ventilation
More than 90% of patients reach the nadir of
their function within two to four weeks, with
return of function occurring slowly over
weeks to months
Two-thirds of patients develop the neurologic
symptoms 2-4 weeks after what appears to be a
benign respiratory or gastrointestinal infection
The initial symptoms are fine paresthesias in
the toes and fingertips, followed by lower
extremity weakness that may ascend over
hours to days to involve the arms, cranial
nerves, and in severe cases the muscles of
respiration
Clinical manifestations
Autonomic nervous system dysfunction
results from alterations in sympathetic
and parasympathetic nervous systems.
Results in respiratory muscle paralysis,
hypotension, hypertension, bradycardia,
heart block, asystole.
Involvement of lower brainstem leads to
facial and eye weakness
Physical Examination
 Symmetric limb weakness with diminished or absent
reflexes
 Minimal loss of sensation despite paresthesias
 Signs of autonomic dysfunction are present in 50
percent of patients, including
 Cardiac dysrhythmias (asystole, bradycardia, sinus
tachycardia, and atrial/ventricular
tachyarrhythmias)
 Orthostatic hypotension
 Transient or persistent hypertension
 Paralytic ileus
 Bladder dysfunction
 Abnormal sweating
DIAGNOSTIC STUDIES
Electrophysiologic studies are the most specific
and sensitive tests for diagnosis of the disease
They demonstrate a variety of abnormalities
indicating evolving multifocal demyelination
 Slowed nerve conduction velocities
 Partial motor conduction block
 Abnormal temporal dispersion
 Prolonged distal latencies
A normal study after several days of symptoms,
makes the diagnosis of Guillain-Barré syndrome
unlikely
DIAGNOSTIC STUDIES
After the first week of symptoms, analysis of the
cerebrospinal fluid (CSF) typically reveals
 normal pressures
 few cells (typically mononuclear)
 an elevated protein conc. (greater than 50 mg/dL)
Early in the course (less than one week), protein
levels may not yet be elevated, but only rarely
do they remain persistently normal
If CSF pleocytosis is noted, other diseases
associated with Guillain-Barré syndrome eg,
HIV infection, Lyme disease, malignancy, and
sarcoidosis should be considered
Therapeutic management
 Ventilator support!
 Plasmapheresis used within the first 2 weeks
of onset. If treated within the first 2 weeks,
LOS of morbidity is reduced. After three
weeks, plasmapharesis no benefit.
 IV immunoglobin
 Nutritional support (TF, TPN, Diet)
Variants
Acute inflammatory
demyelinating polyneuropathy (AID
P) is the most common form of GBS,
and the term is often used
synonymously with GBS.
It is caused by an autoimmune response
directed against Schwann
cell membranes.
Miller Fisher syndrome (MFS) is a
rare variant of GBS. Accounting for
about 5% of GBS cases, it manifests as a
descending paralysis, proceeding in the
reverse order of the more common
form of GBS.
 Acute motor axonal
neuropathy (AMAN), also known
as Chinese paralytic syndrome, attacks
motor nodes of Ranvier and is prevalent
in China and Mexico.
 It is probably due to an auto-immune
response directed against the
axoplasm of peripheral nerves.
Acute motor sensory axonal
neuropathy (AMSAN) is similar to
AMAN, but also affects sensory nerves
with severe axonal damage.
Acute panautonomic neuropathy is
the rarest variant of GBS, sometimes
accompanied by encephalopathy.
Bickerstaff's brainstem
encephalitis (BBE), a further variant of
Guillain–Barré syndrome, is
characterized by acute onset
of ophthalmoplegia, ataxia, disturbance
of consciousness, hyperreflexia
or Babinski's sign.

Guillain barré syndrome

  • 1.
  • 2.
  • 3.
    It has anannual incidence of 0.6 to 2.4 cases per 100,000 population and occurs at all ages and in both sexes With the marked decline in the incidence of polio, Guillain-Barré syndrome is now the most common cause of acute flaccid paralysis in healthy people is an acute inflammatory demyelinating polyneuropathy characterized by progressive muscle weakness and areflexia
  • 4.
    Guillain-Barre’ Syndrome  Post-infectiouspolyneuropathy; ascending polyneuropathic paralysis  An acute, rapidly progressing and potentially fatal form of polyneuritis
  • 5.
    Guillain-Barre’ Syndrome  Affectsthe peripheral nervous system 
  • 7.
    PATHOGENESIS Peripheral nerve demyelinationin Guillain-Barré syndrome is believed to be immunologically mediated Humoral factors and cell-mediated immune phenomena have been implicated in the damage of myelin and/or the myelin-producing Schwann cells
  • 9.
    Guillain-Barre’ T-cell sensitization occurswhich causes loss of myelin which disrupts nerve impulses Loss of myelin, edema and inflammation of the affected nerves, causes a loss of neurotransmission to the periphery. 85% of patients recover with supportive care.
  • 11.
    Guillain-Barré syndrome hasbeen reported to follow  vaccinations  epidural anesthesia  thrombolytic agents It has been associated with some systemic processes, such as  Hodgkin's disease  SLE  Sarcoidosis, and  infection with Campylobacter, Lyme disease, EBV, CMV, HSV, mycoplasma, and recently acquired HIV infection
  • 12.
    Campylobacter infection is themost commonly identified precipitant of Guillain-Barré syndrome A case-control study involving 103 patients with the disease found that 26% of affected individuals had evidence of recent C. jejuni infection compared with 2% of household and 1% of age-matched controls Seventy percent of those infected with C. jejuni reported a diarrheal illness within 12 weeks before the onset of the neurologic illness
  • 15.
    Clinical Manifestations  Usuallydevelop 1 to 3 weeks after URI or GI infection  Weakness of lower extremities (symmetrically)  Parathesia (numbness and tingling), followed by paralysis  Hypotonia and areflexia (absence of reflexes)  Pain in the form of muscles cramps or hyperesthesias (worse at night).
  • 16.
    Early in thecourse, patients frequently complain of aching or sciatica-like lower back or leg pain At some point during their illness, up to 25 percent of patients require mechanical ventilation More than 90% of patients reach the nadir of their function within two to four weeks, with return of function occurring slowly over weeks to months
  • 17.
    Two-thirds of patientsdevelop the neurologic symptoms 2-4 weeks after what appears to be a benign respiratory or gastrointestinal infection The initial symptoms are fine paresthesias in the toes and fingertips, followed by lower extremity weakness that may ascend over hours to days to involve the arms, cranial nerves, and in severe cases the muscles of respiration
  • 18.
    Clinical manifestations Autonomic nervoussystem dysfunction results from alterations in sympathetic and parasympathetic nervous systems. Results in respiratory muscle paralysis, hypotension, hypertension, bradycardia, heart block, asystole. Involvement of lower brainstem leads to facial and eye weakness
  • 20.
    Physical Examination  Symmetriclimb weakness with diminished or absent reflexes  Minimal loss of sensation despite paresthesias  Signs of autonomic dysfunction are present in 50 percent of patients, including  Cardiac dysrhythmias (asystole, bradycardia, sinus tachycardia, and atrial/ventricular tachyarrhythmias)  Orthostatic hypotension  Transient or persistent hypertension  Paralytic ileus  Bladder dysfunction  Abnormal sweating
  • 21.
    DIAGNOSTIC STUDIES Electrophysiologic studiesare the most specific and sensitive tests for diagnosis of the disease They demonstrate a variety of abnormalities indicating evolving multifocal demyelination  Slowed nerve conduction velocities  Partial motor conduction block  Abnormal temporal dispersion  Prolonged distal latencies A normal study after several days of symptoms, makes the diagnosis of Guillain-Barré syndrome unlikely
  • 22.
    DIAGNOSTIC STUDIES After thefirst week of symptoms, analysis of the cerebrospinal fluid (CSF) typically reveals  normal pressures  few cells (typically mononuclear)  an elevated protein conc. (greater than 50 mg/dL) Early in the course (less than one week), protein levels may not yet be elevated, but only rarely do they remain persistently normal If CSF pleocytosis is noted, other diseases associated with Guillain-Barré syndrome eg, HIV infection, Lyme disease, malignancy, and sarcoidosis should be considered
  • 23.
    Therapeutic management  Ventilatorsupport!  Plasmapheresis used within the first 2 weeks of onset. If treated within the first 2 weeks, LOS of morbidity is reduced. After three weeks, plasmapharesis no benefit.  IV immunoglobin  Nutritional support (TF, TPN, Diet)
  • 26.
    Variants Acute inflammatory demyelinating polyneuropathy(AID P) is the most common form of GBS, and the term is often used synonymously with GBS. It is caused by an autoimmune response directed against Schwann cell membranes.
  • 27.
    Miller Fisher syndrome(MFS) is a rare variant of GBS. Accounting for about 5% of GBS cases, it manifests as a descending paralysis, proceeding in the reverse order of the more common form of GBS.
  • 28.
     Acute motoraxonal neuropathy (AMAN), also known as Chinese paralytic syndrome, attacks motor nodes of Ranvier and is prevalent in China and Mexico.  It is probably due to an auto-immune response directed against the axoplasm of peripheral nerves.
  • 29.
    Acute motor sensoryaxonal neuropathy (AMSAN) is similar to AMAN, but also affects sensory nerves with severe axonal damage. Acute panautonomic neuropathy is the rarest variant of GBS, sometimes accompanied by encephalopathy.
  • 30.
    Bickerstaff's brainstem encephalitis (BBE),a further variant of Guillain–Barré syndrome, is characterized by acute onset of ophthalmoplegia, ataxia, disturbance of consciousness, hyperreflexia or Babinski's sign.